Former Georgia CTSA KL2 Scholar Serves as a Principal Investigator in Phase 3 Trial for HIV-Prevention Drug
Lenacapavir reduced HIV infections by 96%. “Because adherence to oral products can be challenging for some people, twice-yearly injectable lenacapavir for PrEP has the potential to be one of the most impactful interventions we could have to drive down new infections and bring us closer to ending the HIV epidemic in the United States,” said former Georgia CTSA KL2 Scholar Colleen Kelley, MD, MPH, Emory and a PURPOSE 2 Principal Investigator.